Cargando…

A blocking ELISA based on virus-like nanoparticles chimerized with an antigenic epitope of ASFV P54 for detecting ASFV antibodies

African swine fever virus (ASFV) is a highly lethal pathogen of domestic and wild pigs. Due to no vaccines or drugs available, early accurate diagnosis and eradication of infected animals are the most important measures for ASFV prevention and control. Bluetongue virus (BTV) core-like particles (CLP...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Chaohua, Cao, Chenfu, Xu, Zhichao, Lin, Yanxing, Wu, Jiang, Weng, Qiaoyu, Liu, Zheng, Jin, Ye, Chen, Peng, Hua, Qunyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651890/
https://www.ncbi.nlm.nih.gov/pubmed/37968284
http://dx.doi.org/10.1038/s41598-023-47068-x
_version_ 1785147648662044672
author Huang, Chaohua
Cao, Chenfu
Xu, Zhichao
Lin, Yanxing
Wu, Jiang
Weng, Qiaoyu
Liu, Zheng
Jin, Ye
Chen, Peng
Hua, Qunyi
author_facet Huang, Chaohua
Cao, Chenfu
Xu, Zhichao
Lin, Yanxing
Wu, Jiang
Weng, Qiaoyu
Liu, Zheng
Jin, Ye
Chen, Peng
Hua, Qunyi
author_sort Huang, Chaohua
collection PubMed
description African swine fever virus (ASFV) is a highly lethal pathogen of domestic and wild pigs. Due to no vaccines or drugs available, early accurate diagnosis and eradication of infected animals are the most important measures for ASFV prevention and control. Bluetongue virus (BTV) core-like particles (CLPs) are non-infectious hollow nanoparticles assembled from the BTV VP3 and VP7 proteins, which could be used as a platform for presenting foreign epitopes. In this study, the secondary structure of BTV VP7 protein was analyzed and predicted using the IEDB Analysis resource. Based on the prediction results of the VP7 protein, the chimeric CLPs with an ASFV P54 epitope were successfully prepared through the BAC-to-BAC baculovirus expression system and sucrose gradient centrifugation. Based on the chimeric CLPs and mAb 2E4 against AFSV P54 epitope, a blocking ELISA for detecting AFSV antibodies was established, and its reaction conditions were optimized. Through comprehensive evaluation of the method, the results showed the chimeric CLPs-based blocking ELISA displayed the best detection performance, with an AUC of 0.9961, a sensitivity of 97.65%, and a specificity of 95.24% in ROC analysis. Compared with western blot and a commercial c-ELISA for detecting anti-ASFV antibodies, this method had an excellent agreement of 96.35% (kappa value = 0.911) and 97.76% (kappa value = 0.946) with the other tests, respectively. This ELISA also had high repeatability, with CV < 10%, and no cross-reaction with the serum antibodies against other swine viruses or Orbivirus. In brief, this was the first report on developing a blocking ELISA based on virus-like nanoparticles chimerized with an antigenic epitope of ASFV P54 for serological diagnosis of ASFV.
format Online
Article
Text
id pubmed-10651890
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-106518902023-11-15 A blocking ELISA based on virus-like nanoparticles chimerized with an antigenic epitope of ASFV P54 for detecting ASFV antibodies Huang, Chaohua Cao, Chenfu Xu, Zhichao Lin, Yanxing Wu, Jiang Weng, Qiaoyu Liu, Zheng Jin, Ye Chen, Peng Hua, Qunyi Sci Rep Article African swine fever virus (ASFV) is a highly lethal pathogen of domestic and wild pigs. Due to no vaccines or drugs available, early accurate diagnosis and eradication of infected animals are the most important measures for ASFV prevention and control. Bluetongue virus (BTV) core-like particles (CLPs) are non-infectious hollow nanoparticles assembled from the BTV VP3 and VP7 proteins, which could be used as a platform for presenting foreign epitopes. In this study, the secondary structure of BTV VP7 protein was analyzed and predicted using the IEDB Analysis resource. Based on the prediction results of the VP7 protein, the chimeric CLPs with an ASFV P54 epitope were successfully prepared through the BAC-to-BAC baculovirus expression system and sucrose gradient centrifugation. Based on the chimeric CLPs and mAb 2E4 against AFSV P54 epitope, a blocking ELISA for detecting AFSV antibodies was established, and its reaction conditions were optimized. Through comprehensive evaluation of the method, the results showed the chimeric CLPs-based blocking ELISA displayed the best detection performance, with an AUC of 0.9961, a sensitivity of 97.65%, and a specificity of 95.24% in ROC analysis. Compared with western blot and a commercial c-ELISA for detecting anti-ASFV antibodies, this method had an excellent agreement of 96.35% (kappa value = 0.911) and 97.76% (kappa value = 0.946) with the other tests, respectively. This ELISA also had high repeatability, with CV < 10%, and no cross-reaction with the serum antibodies against other swine viruses or Orbivirus. In brief, this was the first report on developing a blocking ELISA based on virus-like nanoparticles chimerized with an antigenic epitope of ASFV P54 for serological diagnosis of ASFV. Nature Publishing Group UK 2023-11-15 /pmc/articles/PMC10651890/ /pubmed/37968284 http://dx.doi.org/10.1038/s41598-023-47068-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Huang, Chaohua
Cao, Chenfu
Xu, Zhichao
Lin, Yanxing
Wu, Jiang
Weng, Qiaoyu
Liu, Zheng
Jin, Ye
Chen, Peng
Hua, Qunyi
A blocking ELISA based on virus-like nanoparticles chimerized with an antigenic epitope of ASFV P54 for detecting ASFV antibodies
title A blocking ELISA based on virus-like nanoparticles chimerized with an antigenic epitope of ASFV P54 for detecting ASFV antibodies
title_full A blocking ELISA based on virus-like nanoparticles chimerized with an antigenic epitope of ASFV P54 for detecting ASFV antibodies
title_fullStr A blocking ELISA based on virus-like nanoparticles chimerized with an antigenic epitope of ASFV P54 for detecting ASFV antibodies
title_full_unstemmed A blocking ELISA based on virus-like nanoparticles chimerized with an antigenic epitope of ASFV P54 for detecting ASFV antibodies
title_short A blocking ELISA based on virus-like nanoparticles chimerized with an antigenic epitope of ASFV P54 for detecting ASFV antibodies
title_sort blocking elisa based on virus-like nanoparticles chimerized with an antigenic epitope of asfv p54 for detecting asfv antibodies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651890/
https://www.ncbi.nlm.nih.gov/pubmed/37968284
http://dx.doi.org/10.1038/s41598-023-47068-x
work_keys_str_mv AT huangchaohua ablockingelisabasedonviruslikenanoparticleschimerizedwithanantigenicepitopeofasfvp54fordetectingasfvantibodies
AT caochenfu ablockingelisabasedonviruslikenanoparticleschimerizedwithanantigenicepitopeofasfvp54fordetectingasfvantibodies
AT xuzhichao ablockingelisabasedonviruslikenanoparticleschimerizedwithanantigenicepitopeofasfvp54fordetectingasfvantibodies
AT linyanxing ablockingelisabasedonviruslikenanoparticleschimerizedwithanantigenicepitopeofasfvp54fordetectingasfvantibodies
AT wujiang ablockingelisabasedonviruslikenanoparticleschimerizedwithanantigenicepitopeofasfvp54fordetectingasfvantibodies
AT wengqiaoyu ablockingelisabasedonviruslikenanoparticleschimerizedwithanantigenicepitopeofasfvp54fordetectingasfvantibodies
AT liuzheng ablockingelisabasedonviruslikenanoparticleschimerizedwithanantigenicepitopeofasfvp54fordetectingasfvantibodies
AT jinye ablockingelisabasedonviruslikenanoparticleschimerizedwithanantigenicepitopeofasfvp54fordetectingasfvantibodies
AT chenpeng ablockingelisabasedonviruslikenanoparticleschimerizedwithanantigenicepitopeofasfvp54fordetectingasfvantibodies
AT huaqunyi ablockingelisabasedonviruslikenanoparticleschimerizedwithanantigenicepitopeofasfvp54fordetectingasfvantibodies
AT huangchaohua blockingelisabasedonviruslikenanoparticleschimerizedwithanantigenicepitopeofasfvp54fordetectingasfvantibodies
AT caochenfu blockingelisabasedonviruslikenanoparticleschimerizedwithanantigenicepitopeofasfvp54fordetectingasfvantibodies
AT xuzhichao blockingelisabasedonviruslikenanoparticleschimerizedwithanantigenicepitopeofasfvp54fordetectingasfvantibodies
AT linyanxing blockingelisabasedonviruslikenanoparticleschimerizedwithanantigenicepitopeofasfvp54fordetectingasfvantibodies
AT wujiang blockingelisabasedonviruslikenanoparticleschimerizedwithanantigenicepitopeofasfvp54fordetectingasfvantibodies
AT wengqiaoyu blockingelisabasedonviruslikenanoparticleschimerizedwithanantigenicepitopeofasfvp54fordetectingasfvantibodies
AT liuzheng blockingelisabasedonviruslikenanoparticleschimerizedwithanantigenicepitopeofasfvp54fordetectingasfvantibodies
AT jinye blockingelisabasedonviruslikenanoparticleschimerizedwithanantigenicepitopeofasfvp54fordetectingasfvantibodies
AT chenpeng blockingelisabasedonviruslikenanoparticleschimerizedwithanantigenicepitopeofasfvp54fordetectingasfvantibodies
AT huaqunyi blockingelisabasedonviruslikenanoparticleschimerizedwithanantigenicepitopeofasfvp54fordetectingasfvantibodies